CSIMarket
 


Nutriband Inc   (NTRB)
Other Ticker:  
 

Nutriband Inc 's Working Capital Ratio

NTRB's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




NTRB Working Capital Ratio (Oct 31 2022)
III. Quarter
(Jul 31 2022)
I. Quarter
(Apr 30 2022)
I. Quarter
(Oct 31 2021)
III. Quarter
(Jul 31 2021)
II. Quarter
Y / Y Current Liabilities Change -71.13 % -68.59 % -72.91 % -64.49 % 203.08 %
Y / Y Current Assets Change 478.03 % 340.29 % 1377.43 % 1740.16 % 571.06 %
Working Capital Ratio MRQ 4.62 5.24 6.74 6.62 0.23
Overall Ranking # 1223 # 0 # 1237 # 1133 #
Seq. Current Liabilities Change -3.21 % 13.81 % -23.27 % -65.85 % 5.33 %
Seq. Current Assets Change -14.75 % -11.37 % -21.97 % 880.39 % -35.06 %



Working Capital Ratio third quarter 2022 Comment
Regardless of the sequential decrease in Current Liabilities, Working Capital Ratio detoriated to 4.62 below company average Working Capital Ratio.

Within Biotechnology & Pharmaceuticals industry 145 other companies have achieved higher Working Capital Ratio than Nutriband Inc in third quarter 2022. While Working Capital Ratio total ranking has deteriorated compare to the prior quarter from 0 to 1223.

Explain Working Capital Ratio
Where is NTRB most successful ?
Working Capital Ratio NTRB on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 146
Healthcare Sector # 541
Overall Market # 1223


Working Capital Ratio Statistics
High Average Low
18.92 2.78 0.02
(Jul 31 2018)   (Jan 31 2020)




Financial Statements
Nutriband Inc 's Current Liabilities $ 1 Millions Visit NTRB's Balance sheet
Nutriband Inc 's Current Assets $ 4 Millions Visit NTRB's Balance sheet
Source of NTRB's Sales Visit NTRB's Sales by Geography


Cumulative Nutriband Inc 's Working Capital Ratio

NTRB's Working Capital Ratio for the trailling 12 Months

NTRB Working Capital Ratio

(Oct 31 2022)
III. Quarter
(Jul 31 2022)
I. Quarter
(Apr 30 2022)
I. Quarter
(Oct 31 2021)
III. Quarter
(Jul 31 2021)
II. Quarter
Y / Y Current Liabilities TTM Growth -71.13 % -68.59 % -72.91 % -64.49 % 203.08 %
Y / Y Current Assets TTM Growth 478.03 % 340.29 % 1377.43 % 1740.16 % 571.06 %
Working Capital Ratio TTM 5.82 3.06 1.81 0.91 0.21
Total Ranking TTM # 775 # 1719 # 2663 # 3727 #
Seq. Current Liabilities TTM Growth -3.21 % 13.81 % -23.27 % -65.85 % 5.33 %
Seq. Current Assets TTM Growth -14.75 % -11.37 % -21.97 % 880.39 % -35.06 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis NTRB Current Assets average more than doubled by 478.03 % in III. Quarter year on year, while Current Liabilities decreased to $1 millions, this led to increase in in Nutriband Inc 's Working Capital Ratio to 5.82, Working Capital Ratio remained below NTRB average.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 118 other companies have achieved higher Working Capital Ratio than Nutriband Inc . While overall ranking remained unchanged compare to previous quarter at no. 775.

Explain Working Capital Ratio
Where is NTRB most successful ?
Working Capital Ratio NTRB on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 119
Healthcare Sector # 456
Within the Market # 775


TTM Working Capital Ratio Statistics
High Average Low
5.48 1.22 0.08
(Oct 31 2022)   (Oct 31 2020)




Companies with similar Working Capital Ratio in the quarter ending Oct 31 2022, within Biotechnology & Pharmaceuticals Industry Working Capital RatioOct 31 2022 MRQ Current AssetsOct 31 2022 MRQ Current Liabilities
Chase Corporation  12.42 $ 438.898  Millions$ 35.328  Millions
Ginkgo Bioworks Holdings Inc   11.71 $ 1,462.003  Millions$ 124.818  Millions
Allogene Therapeutics Inc   11.64 $ 569.061  Millions$ 48.872  Millions
Aura Biosciences Inc   11.63 $ 115.908  Millions$ 9.964  Millions
Vicarious Surgical Inc   11.25 $ 131.332  Millions$ 11.678  Millions
Pacific Biosciences Of California Inc   11.19 $ 913.896  Millions$ 81.649  Millions
Omega Therapeutics Inc   10.96 $ 161.038  Millions$ 14.698  Millions
Cytek Biosciences Inc   10.70 $ 443.859  Millions$ 41.494  Millions
Caribou Biosciences Inc   10.65 $ 306.922  Millions$ 28.814  Millions
Scholar Rock Holding Corp  10.60 $ 357.612  Millions$ 33.736  Millions
Fennec Pharmaceuticals Inc   10.30 $ 30.153  Millions$ 2.927  Millions
Passage Bio inc   10.29 $ 222.524  Millions$ 21.619  Millions
Pulse biosciences inc   10.17 $ 71.161  Millions$ 6.998  Millions
Editas Medicine inc   10.09 $ 426.629  Millions$ 42.289  Millions
Pluri Inc   9.91 $ 49.723  Millions$ 5.018  Millions
Humacyte Inc   9.75 $ 174.612  Millions$ 17.906  Millions
Inmune Bio Inc   9.67 $ 66.658  Millions$ 6.895  Millions
Isoplexis Corporation  9.59 $ 97.623  Millions$ 10.182  Millions
Surrozen Inc   9.56 $ 82.719  Millions$ 8.654  Millions
Tscan Therapeutics Inc   9.54 $ 141.177  Millions$ 14.799  Millions
Solid Biosciences Inc   9.51 $ 147.509  Millions$ 15.510  Millions
Rapid Micro Biosystems Inc   9.50 $ 144.577  Millions$ 15.212  Millions
Dbv Technologies S a   9.41 $ 225.695  Millions$ 23.984  Millions
Revolution Medicines Inc   9.21 $ 675.108  Millions$ 73.271  Millions
Scientific Industries Inc  9.16 $ 14.506  Millions$ 1.584  Millions
Invivyd Inc   9.14 $ 421.596  Millions$ 46.126  Millions
Neogen Corporation  9.07 $ 607.907  Millions$ 67.004  Millions
Lakeland Industries Inc   8.97 $ 114.228  Millions$ 12.741  Millions
Tenaya Therapeutics Inc   8.87 $ 157.067  Millions$ 17.716  Millions
Voyager Therapeutics Inc   8.85 $ 146.942  Millions$ 16.612  Millions

Date modified: 2022-12-05T00:34:49+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

BBY's Profile

Stock Price

BBY's Financials

Business Description

Fundamentals

Charts & Quotes

BBY's News

Suppliers

BBY's Competitors

Customers & Markets

Economic Indicators

BBY's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071